N@N

Tripp Levy PLLC Announces Shareholder Lawsuit against Talecris Biotherapeutics

^{Published on 2010-06-15 12:45:05 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--Tripp Levy PLLC announces that a lawsuit was filed on behalf of shareholders of Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) alleging breaches of fiduciary duties by the Board of Directors of Talecris related to Talecrisa™ entry into an agreement to be acquired by Grifols, S.A. in a transaction valued at approximately $3.4 billion.

Under the proposed agreement, Grifols will acquire all of the common stock of Talecris for $19.00 in cash and 0.641 newly-issued non-voting Grifolsa™ shares for each Talecris share. An affiliate of Cerberus Capital Management, L.P., which owns approximately 49% of Talecris common stock, has entered into an agreement to vote in favor of the transaction.

The lawsuit concerns whether Talecrisa™ board of directors allegedly failed to maximize shareholder value and obtain the best price possible for Talecrisa™ shareholders before entering into the agreement with Grifols.

If you own Talecris common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact

Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.